Skip to main content


The latest research in type 1 diabetes, type 2 diabetes, prediabetes, and beyond. Here you’ll find information on experimental therapies, new data and results, and scientific findings.

What's new


Zosano Pharma is making early progress with an innovative patch-based glucagon delivery system for severe hypoglycemia, recently announcing that it has completed enrollment for a phase 2 trial. The idea is to deliver glucagon through a coin-sized patch (about the size of a US quarter) that is applied to the skin.  Continue Reading »

Stem Cells

There was a lot of interest this ADA in the Harvard Stem Cell Institute's diabetes research (not yet in humans), which has previously shown the ability to produce mature, insulin-producing beta cells from human stem cells. These beta cells can effectively cure type 1 diabetes in mice... Continue Reading »

ADA Scientific Sessions

Kicking off this weekend, what are we most excited about for this year’s ADA? Continue Reading »

Pathways Initiative

Starting in 2012, the American Diabetes Association established the Pathway to Stop Diabetes initiative, a $1.6 million grant (paid over five years) to support the research of young up-and-coming scientists who are committed to working on innovative projects in diabetes. The Pathway Award is in many ways a beacon of hope for diabetes researchers navigating the present research-funding climate... Continue Reading »

Helmsley Charitable Trust

How this initiative aims to bring actionable recommendations from overwhelming data. Continue Reading »

DiAs system, artificial pancreas

Twitter Summary: Wearing UVA’s DiAs #artificialpancreas in a 3-month study testing overnight and 24-hr closed-loop at home; learnings, surprises, next steps Continue Reading »

Helmsley Charitable Trust

Plus, their report on the greatest challenges and opportunities in the field. Continue Reading »


After the rapid-acting inhaled insulin Afrezza launched this February, we have been very eager to learn more about how this new product impacts patients’ day-to-day diabetes management. We recently spoke with Ana Ortiz (a type 1 patient) and Bill Kinder (a type 2 patient), two Afrezza users with very different backgrounds... Continue Reading »